1. What Pharmaceutical Portfolio Management Actually Is (and What Most Teams Get Wrong) Pharmaceutical portfolio management is the discipline of […]
How secondary pharmaceutical patents work, why they survive litigation, and what evergreening debates actually get wrong about post-approval R&D economics
A technical deep dive for pharma IP teams, R&D leads, and institutional investors on the world’s most consequential pharmaceutical patent
A comparative deep dive for pharma and biotech IP teams, R&D leads, and institutional investors navigating the two most consequential
The Economic Imperative of Time In the pharmaceutical sector, time is a tangible asset with a valuation that often exceeds
1. The Pricing Crisis in Numbers The United States spends more per capita on prescription drugs than any other OECD
Precision Medicine Drug Pricing: The Complete IP, Patent, and Market Access Playbook Read Post »
A strategic guide to patent expiry, lifecycle defense, and the economics of generic competition — for executives, investors, and analysts
What Happens When a Drug Patent Expires? Understanding Drug Patent Life Read Post »
1. What a Tentative Approval Actually Means (and What It Doesn’t) A Tentative Approval (TA) letter from the FDA means
FDA Tentative Approval: The Generic Drug Strategist’s Complete Playbook Read Post »
The three largest pharmacy benefit managers, CVS Caremark, Express Scripts (now Evernorth, the health services subsidiary of Cigna), and OptumRx
Sign in or create a free account to read this DrugPatentWatch article
